Screener
DaVita DVA U S Dialysis — G&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by DaVita in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: DaVita’s 10-K, filed February 11, 2026.
- Filed
- Feb 10, 2026, 7:00 PM EST
- Fiscal year
- FY2025
- Accession
- 0000927066-26-000012
| Line item | Year ended December 31, 2025 | Year ended December 31, 2024 | Year ended December 31, 2023 |
|---|---|---|---|
| Significant segment expenses: | |||
| U.S. dialysis | |||
| Patient care costs | $7,854,234 | $7,497,576 | $7,394,640 |
| General and administrative | 1,253,298 | 1,173,990 | 1,102,072 |
| Depreciation and amortization | 633,396 | 661,181 | 695,674 |
| Other segment items(1) | (32,217) | (63,037) | (29,966) |
| U.S. dialysis segment expenses | 9,708,711 | 9,269,710 | 9,162,420 |
| Other - Ancillary services expenses(2) | 1,829,907 | 1,427,833 | 1,307,970 |
Item 16. Form 10-K Summary
FAQ
- What is DaVita's u s dialysis — G&A?
- DaVita (DVA) reported u s dialysis — G&A of $313.32M in Q4 2025.
- How has DaVita's u s dialysis — G&A changed year-over-year?
- DaVita's u s dialysis — G&A increased by 6.8% year-over-year, from $293.5M to $313.32M.
- What is the long-term trend for DaVita's u s dialysis — G&A?
- Over 3 years (2022 to 2025), DaVita's u s dialysis — G&A has grown at a 6.5% compound annual growth rate (CAGR), from $1.04B to $1.25B.
- What does u s dialysis — G&A mean?
- Represents the indirect costs of running the dialysis segment, including corporate overhead, management salaries, legal, and administrative support functions. These costs are necessary to support the infrastructure of the business.
Ask your AI about DaVita's u s dialysis — g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude